From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in skin cancer
In the context of the phase 2 SWOG S1801 trial, the efficacy of neoadjuvant-adjuvant administration of pembrolizumab was compared to adjuvant treatment alone, specifically focusing on the achievement of pathological
Professor Jean-François Baurain is pleased to provide a summary and analysis of the presentations from the mini-oral session on melanomas at ESMO2023.
The SECOMBIT trial assessed the efficacy of immunotherapy
In-depth stories about skin cancer
In this discussion, Prof Jean-François Beaurain, a medical oncologist at Cliniques Universitaires Saint-Luc, Brussels, and Dr Winan Van Houdt, a surgical oncologist at the Netherlands Cancer Institute, shed light on
During an ESMO presentation, Prof. Paolo Ascierto, a medical oncologist at the National Cancer Institute of Naples, Italy, provided a 5-year update on the SECOMBIT study, focusing on total PFS,
Skin cancer poster selection
Nathalie Vanlaer, Ph.D. student at VUB Brussels presented a single-centre prospective study evaluating neurocognitive functioning in cancer survivors who were diagnosed with stage III/IV cancer of any type, and who
There are no active treatment options for patients with progressive melanoma brain metastases who have failed treatment with immunotherapy and BRAF-/MEK inhibitors. Dr Iris Dirven, medical oncologist at UZ Brussels
Dr Emilie Gérard, medical oncologist at the Saint-André University hospital of Bordeaux, France presented the results from the French study TOSCA, evaluating cemiplimab versus historical systemic treatments for locally advanced
Dr Paolo A. Ascierto, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, Italy presented the updated 7-year
With the educational support of: